Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Rhesus monkey|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Recombinant human wild type p53 protein expressed in E. coli.|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|ChIP assay (ChIP)||1-3 µg x 10^6 cells|
|Immunohistochemistry (Paraffin) (IHC (P))||Assay-Dependent|
|Western Blot (WB)||Assay-Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody reacts with mutant and wild form p53. It reacts with an epitope at aa 20-25.
Staining of formalin-fixed paraffin-embedded tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 20 min followed by cooling at room temperature for 20 min.
Recommended positive controls include SK-BR-3 cells, MDA-231 cells, and colon carcinoma.
Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA- Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seem to have to effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.
IP-MS enrichment of TP53 (LFQ intensity): TP53 was enriched 478-fold from BT549 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Product # 90409) and TP53 antibody (Product # AHO0152). STRING database was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound.
AHO0152 was used in immunohistochemistry to assess a protocol for acquiring portal venous blood through endoscopic ultrasound
|Catenacci DV,Chapman CG,Xu P,Koons A,Konda VJ,Siddiqui UD,Waxman I||Gastroenterology (149:1794)||2015|
Enhanced anticancer activity and circumvention of resistance mechanisms by novel polymeric/ phospholipidic nanocarriers of doxorubicin.
AHO0152 was used in western blot to describe a new polymeric-phospholipidic hybrid delivery system which enhanced the accumulation and activity of Dox in all tested cancer cell lines
|Senkiv Y,Riabtseva A,Heffeter P,Boiko N,Kowol CR,Jungwith U,Shlyakhtina Y,Garasevych SG,Mitina N,Berger W,Zaichenko A,Stoika R||Journal of biomedical nanotechnology (10:1369)||2014|
p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes.
AHO0152 was used in western blot to develop a method to quantify p53 degradation activity of E6 in vivo and assess HPV variants.
|Mesplède T,Gagnon D,Bergeron-Labrecque F,Azar I,Sénéchal H,Coutlée F,Archambault J||Journal of virology (86:94)||2012|
antigen NY-CO-13; cellular tumor antigen p53; mutant tumor protein 53; P53; p53 tumor suppressor; phosphoprotein p53; TP53; transformation-related protein 53; tumor protein 53; tumor suppressor p53; tumor supressor p53
BCC7; EGK_08142; LFS1; P53; TP53; TRP53